The Problem This Solves
⏱️ Manual Morning Prep — 60–90 Minutes Daily
Supply chain analysts pull stock levels, supplier performance, order status, and client risk from disconnected systems every morning before they can make a single decision.
🎯 Opportunity: Shift from Reactive to Proactive
The opportunity is a unified intelligence layer that identifies risk before it escalates — surfacing critical shortages, supplier failures, and client exposure proactively, not after the fact.
📊 Fragmented Intelligence
Answering cross-domain questions — which suppliers are putting which clients at risk, which provinces are most exposed, what happens if a key supplier fails — requires manually combining multiple reports and files. This agent delivers those answers instantly.
👥 No Persona Awareness
The Chief Supply Chain Officer, a Regional Manager, and an Inventory Analyst all need different views of the same data. Today they get the same reports.
Architecture: How It Works
⬡ Master Orchestrator Agent
Reads user intent · Routes to specialist agents · Synthesizes cross-domain intelligence · Generates morning briefings
Inventory Intelligence
Stock, thresholds, cold chain, controlled substances
Supplier Intelligence
On-time rates, exceptions, risk ranking, backups
Order Tracking
Delayed orders, exceptions, urgent shipments
Regional Intelligence
Province, DC, client type, hospital risk
Action Management
Open actions, approvals, escalations
For complex cross-domain queries (e.g. "which suppliers are putting clients at risk"), the orchestrator calls multiple specialist agents simultaneously and synthesizes their responses into one unified answer — crossing inventory, supplier, order, client, and action data in a single response.
Live Agent Outputs — Real Responses from the Prototype
The following are unedited responses produced by the live Copilot Studio agent, querying synthetic data across 5 knowledge sources.
Select a tab to explore each agent query and response.
Med America Supply Chain — CEO Risk Summary
As of May 29, 2026
Prepared by: Supply Chain Intelligence
Intelligence to Action.
🔴 INVENTORY — 8 Products in Crisis
- 🔴 Ciprofloxacin 500mg — 1 day of supply remaining | Antibiotic | DC-ATL at highest risk
- 🔴 Doxycycline 100mg — 1 day of supply remaining | Antibiotic
- 🔴 Amlodipine 5mg — 2 days of supply remaining | Cardiovascular
- 🔴 Adalimumab 40mg — 2 days of supply remaining | ❄️ Cold Chain | Immunology biologic
- 🔴 Atorvastatin 20mg — 3 days of supply remaining | Cardiovascular
- 🔴 Morphine Sulfate 10mg — 3 days of supply remaining | ⚠️ Controlled Substance | Regulatory risk
- 🔴 Trastuzumab 440mg — 3 days of supply remaining | ❄️ Cold Chain | Oncology biologic | Patient safety risk
- 🔴 Insulin Glargine 100u/ml — 4 days of supply remaining | ❄️ Cold Chain | Diabetes | Supplier delayed
🟠 AT RISK INVENTORY — 6 Products Approaching Threshold
- 🟠 Warfarin 5mg — 5 days of supply | Anticoagulant
- 🟠 Salbutamol Inhaler — 5 days of supply | Respiratory
- 🟠 Metformin 850mg — 6 days of supply | Diabetes
- 🟠 Risperidone 2mg — 7 days of supply | Mental Health
- 🟠 Hydromorphone 2mg — 7 days of supply | ⚠️ Controlled Substance
- 🟠 Fentanyl Patch 25mcg — 5 days of supply | ⚠️ Controlled Substance
- 🟠 Rituximab 500mg — 6 days of supply | ❄️ Cold Chain | Oncology biologic
- 🟠 Gabapentin 300mg — 8 days of supply | Neurology
🔴 DELAYED ORDERS — 5 Active (All Flagged Urgent)
- 🔴 ORD-001 — Insulin Glargine 100u/ml | DC-ON | ❄️ Cold Chain | Expected: May 26 — now overdue
- 🔴 ORD-002 — Amlodipine 5mg | DC-ON | Expected: May 26 — now overdue
- 🔴 ORD-003 — Ciprofloxacin 500mg | DC-ATL | Expected: May 28 — overdue
- 🔴 ORD-004 — Adalimumab 40mg | DC-QC-E | ❄️ Cold Chain | Expected: May 27 — overdue
- 🔴 ORD-005 — Trastuzumab 440mg | DC-ON | ❄️ Cold Chain | Expected: May 28 — overdue | Chief escalation active
⚠️ ACTIVE ORDER EXCEPTIONS — 6 Open
- ⚠️ ORD-049 — Insulin Glargine | Short Shipped | Urgent | DC-AB | ❄️ Cold Chain
- ⚠️ ORD-050 — Amlodipine 5mg | Damaged | Urgent | DC-ON
- ⚠️ ORD-051 — Morphine Sulfate 10mg | Wrong Product | Urgent | DC-NL | ⚠️ Controlled Substance — regulatory risk
- ⚠️ ORD-052 — Adalimumab 40mg | Short Shipped | Urgent | DC-ON | ❄️ Cold Chain
- ⚠️ ORD-053 — Ciprofloxacin 500mg | Damaged | DC-BC
- ⚠️ ORD-054 — Trastuzumab 440mg | Short Shipped | Urgent | DC-ON | ❄️ Cold Chain | Oncology — patient impact risk
🟠 SUPPLIER WATCHLIST — 3 Problem Suppliers
- 🔴 BioRx Logistics (S004) — On-time delivery: 60% | 8 open exceptions | Status: AT RISK | Escalated to watchlist
- 🔴 EndoPharm (S008) — On-time delivery: 68% | 6 open exceptions | Status: AT RISK | Performance review scheduled
- 🟠 NovaDist Health (S002) — On-time delivery: 72% | 5 open exceptions | Status: DELAYED | Cold chain supplier | Backup supplier identified
⚡ OPEN ACTIONS — 10 Total
- ⚡ ACT-001 — Reorder Raised | Amlodipine 5mg | 600 units | Status: Open
- ⚡ ACT-002 — Exception Logged | Insulin Glargine short shipped 40 units | NovaDist notified | Status: In Progress
- ⚡ ACT-003 — Supplier Escalated | BioRx Logistics | 60% OTD | Status: Open
- ⚡ ACT-004 — Emergency PO Raised | Ciprofloxacin 800 units | DC-ATL | Status: ⚠️ PENDING APPROVAL
- ⚡ ACT-005 — Expedite Requested | Adalimumab | ImmunoRx notified | Status: In Progress
- ⚡ ACT-006 — Backup Supplier Flagged | Insulin Glargine | NovaDist Backup identified | Status: Open
- ⚡ ACT-007 — Escalated to Chief | Trastuzumab | Sunnybrook Oncology | Patient impact risk | Status: 🔴 ESCALATED
- ⚡ ACT-008 — Reorder Raised | Atorvastatin 20mg | 1,000 units | Status: Open
- ⚡ ACT-009 — Supplier Review Scheduled | EndoPharm | 3 exceptions this month | Status: Scheduled
- ⚡ ACT-010 — Exception Logged | Morphine Sulfate wrong product shipped to NL LTC | Return initiated | Status: In Progress
✅ TOP 5 RECOMMENDED PRIORITIES
- ⚡ Priority 1 — APPROVE Emergency PO (ACT-004): Ciprofloxacin at DC-ATL has 1 day of supply. Emergency PO for 800 units is pending approval — approve immediately.
- ⚡ Priority 2 — CONFIRM Chief Acknowledgement (ACT-007): Trastuzumab exception at Sunnybrook Oncology is escalated. Confirm Chief Supply Chain Officer has acknowledged and a patient safety response is in motion.
- ⚡ Priority 3 — ACTIVATE Backup Supplier (ACT-006): Insulin Glargine is at 4 days of supply with NovaDist delayed. NovaDist Backup (S014) is on track for May 30 — activate now to prevent stockout.
- ⚡ Priority 4 — ADDRESS BioRx Performance (ACT-003): 60% on-time rate and 8 open exceptions exceed acceptable risk thresholds. Contract review and contingency sourcing required.
- ⚡ Priority 5 — RESOLVE Controlled Substance Exception (ACT-010): Wrong product shipped to NL LTC for Morphine Sulfate — regulatory compliance risk. Confirm return is complete and Health Canada reporting obligations are assessed.
Report generated by Supply Chain Intelligence Agent | Intelligence to Action
Date: May 29, 2026 | Confidential — Internal Use Only
🌅 Med America Supply Chain — Morning Briefing
Date: May 28, 2026 | Prepared for: Jaini Desai
📊 SITUATION OVERVIEW
- 🔴 8 CRITICAL inventory products
- 🟠 8 AT RISK inventory products
- 🔴 5 DELAYED orders — all flagged Urgent
- 🟠 7 AT RISK orders
- ⚠️ 6 Active exceptions — 3 Short Shipped, 2 Damaged, 1 Wrong Product
- ⚡ 10 open actions including 1 Chief escalation and 1 Pending Approval
🔴 SECTION 1 — CRITICAL INVENTORY
The following 8 products are at or below safety stock thresholds and require immediate attention:
Non–Cold Chain / Non–Controlled:
- 🔴 Ciprofloxacin 500mg (P002) — 40 units | 1 day of supply | Reorder Status: CRITICAL
- 🔴 Doxycycline 100mg (P003) — 35 units | 1 day of supply | Reorder Status: CRITICAL
- 🔴 Atorvastatin 20mg (P006) — 120 units | 3 days of supply | Reorder Status: CRITICAL
- 🔴 Amlodipine 5mg (P007) — 70 units | 2 days of supply | Reorder Status: CRITICAL
🧊 Cold Chain — Patient Safety Risk:
- 🔴🧊 Insulin Glargine 100u/ml (P016) — 110 units | 4 days of supply | CRITICAL | Cold Chain Required
- 🔴🧊 Trastuzumab 440mg (P036) — 18 units | 3 days of supply | CRITICAL | Cold Chain Required *(Oncology)*
- 🔴🧊 Adalimumab 40mg (P040) — 15 units | 2 days of supply | CRITICAL | Cold Chain Required *(Immunology)*
⚠️ Controlled Substance — Regulatory Risk:
- 🔴⚠️ Morphine Sulfate 10mg (P043) — 80 units | 3 days of supply | CRITICAL | Controlled Substance
🟠 SECTION 2 — AT RISK INVENTORY
The following 8 products are trending toward critical and require monitoring:
- 🟠 Warfarin 5mg (P014) — 170 units | 5 days of supply
- 🟠 Metformin 850mg (P015) — 270 units | 6 days of supply
- 🟠 Salbutamol Inhaler (P019) — 200 units | 5 days of supply
- 🟠 Risperidone 2mg (P026) — 110 units | 7 days of supply
- 🟠 Gabapentin 300mg (P031) — 155 units | 8 days of supply
- 🟠🧊 Rituximab 500mg (P037) — 28 units | 6 days of supply | Cold Chain *(Oncology)*
- 🟠⚠️ Hydromorphone 2mg (P044) — 120 units | 7 days of supply | Controlled Substance
- 🟠⚠️ Fentanyl Patch 25mcg (P046) — 60 units | 5 days of supply | Controlled Substance
🔴 SECTION 3 — DELAYED ORDERS (All Urgent)
All 5 delayed orders carry an Urgent priority flag. Three involve cold chain products:
- 🔴🧊 ORD-001 — Insulin Glargine 100u/ml | Supplier: NovaDist Health | Client: INVIVA Toronto (C029) | DC: DC-ON | Expected: May 26 | Shipment: Cold Chain — PAST DUE
- 🔴 ORD-002 — Amlodipine 5mg | Supplier: CardioSupply Co | Client: Toronto General Hospital (C025) | DC: DC-ON | Expected: May 26 | Shipment: Ground — PAST DUE
- 🔴 ORD-003 — Ciprofloxacin 500mg | Supplier: Pharmex Canada | Client: QEII Health Sciences Halifax (C046) | DC: DC-ATL | Expected: May 28 | Shipment: Ground
- 🔴🧊 ORD-004 — Adalimumab 40mg | Supplier: ImmunoRx Supply | Client: Jewish General Oncology (C039) | DC: DC-QC-E | Expected: May 27 | Shipment: Cold Chain — PAST DUE
- 🔴🧊 ORD-005 — Trastuzumab 440mg | Supplier: OncoBio Canada | Client: Sunnybrook Oncology (C027) | DC: DC-ON | Expected: May 28 | Shipment: Cold Chain
⚡ Escalation Required: ORD-001, ORD-004, and ORD-005 are delayed cold chain orders serving INVIVA and Oncology clinics. These are patient safety risks.
🟠 SECTION 4 — AT RISK ORDERS
- 🟠⚡ ORD-006 — Atorvastatin 20mg | Supplier: CardioSupply Co | Client: Toronto IDA Pharmacy (C020) | DC: DC-ON | Expected: May 29 | Urgent
- 🟠 ORD-007 — Salbutamol Inhaler | Supplier: BioRx Logistics | Client: Brandon Remedy'sRx (C019) | DC: DC-MB | Expected: Jun 1
- 🟠 ORD-008 — Gabapentin 300mg | Supplier: EndoPharm | Client: MS Clinic Toronto (C028) | DC: DC-ON | Expected: May 29
- 🟠⚠️⚡ ORD-009 — Morphine Sulfate 10mg | Supplier: ControlledMed Inc | Client: Brampton LTC Facility (C030) | DC: DC-ON | Expected: May 29 | Urgent | Secure Courier
- 🟠🧊 ORD-010 — Rituximab 500mg | Supplier: OncoBio Canada | Client: Jewish General Oncology (C039) | DC: DC-QC-E | Expected: May 30 | Cold Chain
- 🟠 ORD-011 — Metformin 850mg | Supplier: NovaDist Health | Client: Health Sciences Centre Winnipeg (C017) | DC: DC-MB | Expected: May 28
- 🟠 ORD-012 — Tiotropium Inhaler | Supplier: BioRx Logistics | Client: BC Cancer Agency (C005) | DC: DC-BC | Expected: Jun 2
⚠️ SECTION 5 — ACTIVE ORDER EXCEPTIONS
Six active exceptions are on the board — all require resolution:
- ⚠️🧊 ORD-049 — Exception: Short Shipped | Insulin Glargine | Client: INVIVA Edmonton (C014) | DC: DC-AB | Urgent | Cold Chain — *40 units short*
- ⚠️ ORD-050 — Exception: Damaged | Amlodipine 5mg | Client: Thunder Bay IDA (C032) | DC: DC-ON | Urgent
- ⚠️⚠️ ORD-051 — Exception: Wrong Product | Morphine Sulfate 10mg | Client: NL Long-Term Care (C053) | DC: DC-NL | Urgent | Secure Courier — *Controlled Substance, return initiated*
- ⚠️🧊 ORD-052 — Exception: Short Shipped | Adalimumab 40mg | Client: INVIVA Toronto (C029) | DC: DC-ON | Urgent | Cold Chain
- ⚠️ ORD-053 — Exception: Damaged | Ciprofloxacin 500mg | Client: Prince George Medicine Shoppe (C007) | DC: DC-BC | Ground
- ⚠️🧊 ORD-054 — Exception: Short Shipped | Trastuzumab 440mg | Client: Sunnybrook Oncology (C027) | DC: DC-ON | Urgent | Cold Chain
⚡ ORD-051 requires immediate compliance attention — wrong product shipped for a controlled substance via Secure Courier.
🏭 SECTION 6 — SUPPLIER PERFORMANCE
🔴 CRITICAL SUPPLIERS — Below 70% On-Time Rate:
- 🔴 BioRx Logistics (S004) — On-Time Rate: 60% | Open Exceptions: 8 | Status: AT RISK | Next Delivery: Jun 3 | Contract: Secondary
- 🔴 EndoPharm (S008) — On-Time Rate: 68% | Open Exceptions: 6 | Status: AT RISK | Next Delivery: May 29 | Contract: Preferred
⚡ Both suppliers are below the 70% threshold — systemic supply risk. Escalation is required.
🟠 WATCH SUPPLIERS:
- 🟠 NovaDist Health (S002) — On-Time Rate: 72% | Open Exceptions: 5 | Status: DELAYED | Next Delivery: May 28 | Cold Chain supplier
- 🟠 CardioSupply Co (S003) — On-Time Rate: 85% | Open Exceptions: 3 | Status: AT RISK | Next Delivery: May 30
🟢 PERFORMING SUPPLIERS:
- 🟢 MedCore Pharma (S005) — 96% on-time | 0 exceptions | On Track
- 🟢 Pharmex Canada (S001) — 94% on-time | 1 exception | On Track
- 🟢 ControlledMed Inc (S011) — 93% on-time | 1 exception | On Track
- 🟢 MindMed Supply (S007) — 91% on-time | 1 exception | On Track
- 🟢 OncoBio Canada (S009) — 90% on-time | 1 exception | On Track
⚡ SECTION 7 — OPEN ACTION LOG (10 Actions)
- ⚡ ACT-007 | Escalated to Chief | Trastuzumab exception at Sunnybrook Oncology — patient impact risk | Status: Escalated | Raised: May 26
- ⚡ ACT-004 | Emergency PO Raised | Ciprofloxacin 500mg critical in ATL region — emergency PO 800 units for QEII Health Sciences Halifax | Status: Pending Approval | Raised: May 26
- 🔴 ACT-001 | Reorder Raised | Amlodipine 5mg stock critical — reorder 600 units (CardioSupply, Toronto General Hospital) | Status: Open | Raised: May 24
- 🔴 ACT-008 | Reorder Raised | Atorvastatin 20mg critical — reorder 1,000 units | Status: Open | Raised: May 22
- 🟠 ACT-002 | Exception Logged | Insulin Glargine short shipped 40 units — NovaDist notified (INVIVA Edmonton) | Status: In Progress | Raised: May 25
- 🟠 ACT-005 | Expedite Requested | Adalimumab delayed — expedite request sent to ImmunoRx (Jewish General Oncology) | Status: In Progress | Raised: May 25
- 🟠 ACT-006 | Backup Supplier Flagged | NovaDist delays — NovaDist Backup identified for Insulin Glargine | Status: Open | Raised: May 24
- 🟠 ACT-003 | Supplier Escalated | BioRx Logistics on-time rate dropped to 60% — escalated to watchlist | Status: Open | Raised: May 23
- 🟠 ACT-009 | Supplier Review Scheduled | EndoPharm performance review — 3 exceptions this month | Status: Scheduled | Raised: May 25
- ⚠️ ACT-010 | Exception Logged | Wrong product shipped to NL Long-Term Care (Morphine Sulfate) — return initiated | Status: In Progress | Raised: May 26
🗺️ SECTION 8 — REGIONAL EXPOSURE SNAPSHOT
- 🔴 DC-ON (Mississauga, ON) — Highest exposure: 3 delayed orders, 3 active exceptions, 3 AT RISK orders. Key clients impacted: Toronto General Hospital, INVIVA Toronto, Sunnybrook Oncology
- 🔴 DC-ATL (Moncton, NB) — QEII Health Sciences Halifax (C046) delayed Ciprofloxacin order; Emergency PO pending approval
- 🟠 DC-QC-E (Montreal, QC) — Jewish General Oncology (C039) has delayed Adalimumab (Cold Chain) + AT RISK Rituximab order
- 🟠 DC-AB (Calgary, AB) — INVIVA Edmonton (C014) has an active short-ship exception on Insulin Glargine (Cold Chain)
- 🟠 DC-NL (St. John's, NL) — NL Long-Term Care (C053) affected by wrong product exception for Morphine Sulfate (Controlled Substance)
- 🟠 DC-MB (Winnipeg, MB) — Health Sciences Centre Winnipeg (C017) has AT RISK Metformin order from delayed NovaDist
⚡ TOP 5 RECOMMENDED PRIORITIES FOR TODAY
- 🔴 IMMEDIATE — Approve Emergency PO ACT-004 — Ciprofloxacin for QEII Health Sciences Halifax is at 1 day of supply with a delayed order. The emergency PO for 800 units is pending approval right now.
- 🔴 ESCALATE — Trastuzumab at Sunnybrook Oncology — ACT-007 is already with the Chief. Confirm acknowledgement and ensure replacement shipment is expedited. ORD-054 (short shipped, Cold Chain) and ORD-005 (delayed, Cold Chain) both affect this client.
- 🔴 COLD CHAIN ALERT — Adalimumab & Insulin Glargine — Three delayed/exception Cold Chain orders across DC-ON, DC-QC-E, and DC-AB. Activate NovaDist Backup (S014) for Insulin Glargine and confirm ImmunoRx expedite response for Adalimumab.
- 🔴 CONTROLLED SUBSTANCE — Morphine Sulfate Wrong Product (ORD-051) — Return is initiated but replacement must be dispatched urgently for NL Long-Term Care. Compliance documentation required.
- 🟠 SUPPLIER ACTION — BioRx & EndoPharm — Both are below the 70% on-time threshold with 8 and 6 open exceptions respectively. Initiate formal performance review for BioRx immediately and confirm EndoPharm review (ACT-009) proceeds as scheduled.
Intelligence to Action — Supply Chain Intelligence | May 28, 2026
🏥 Supplier Risk to Critical Care Clients
Supply Chain Intelligence
Report Date: May 29, 2026
Prepared for: Jaini Desai
Scope: Hospitals | Oncology Clinics | INVIVA Infusion Centres | Specialty Clinics (Neurology / Immunology)
⚡ EXECUTIVE SUMMARY
Six suppliers currently pose active risk to critical care clients across the Med America network.
Three carry CRITICAL-level exposure with delayed cold chain shipments, short-shipped exceptions, and direct Chief escalations in progress.
🔴 RANK 1 — NovaDist Health (S002)
Risk Level: CRITICAL
On-Time Delivery Rate: 72%
Open Exceptions: 5
Delivery Status: DELAYED
Shipment Method: Cold Chain ⚠️
Active Risk to Critical Care Clients:
- ORD-001 | DELAYED | Urgent | Cold Chain → INVIVA Toronto (C029) | Expected: 2026-05-26 (OVERDUE)
- ORD-049 | Exception - Short Shipped | Urgent | Cold Chain → INVIVA Edmonton (C014) | Expected: 2026-05-22 (OVERDUE)
- ORD-011 | AT RISK → Health Sciences Centre Winnipeg (C017) | Expected: 2026-05-28
Open Actions:
- ACT-002: Insulin Glargine short shipped by 40 units — INVIVA Edmonton notified (In Progress)
- ACT-006: Backup supplier NovaDist Backup (S014) identified for Insulin — Open
Why This Matters:
NovaDist is the sole Preferred Cold Chain supplier for Insulin Glargine (P016) and related biologics.
Two of three active critical care orders are either DELAYED or Exception - Short Shipped.
Cold chain breach risk is active. INVIVA infusion clients cannot substitute therapies.
Recommended Actions:
- Activate NovaDist Backup (S014) immediately for Insulin orders
- Escalate ORD-001 and ORD-049 to Chief Supply Chain Officer
- Conduct emergency supplier call with NovaDist Health today
🔴 RANK 2 — OncoBio Canada (S009)
Risk Level: CRITICAL
On-Time Delivery Rate: 90%
Open Exceptions: 1
Delivery Status: On Track (but active exception orders outstanding)
Shipment Method: Cold Chain ⚠️
Active Risk to Critical Care Clients:
- ORD-005 | DELAYED | Urgent | Cold Chain → Sunnybrook Oncology (C027) | Expected: 2026-05-28
- ORD-054 | Exception - Short Shipped | Urgent | Cold Chain → Sunnybrook Oncology (C027) | Expected: 2026-05-23 (OVERDUE)
- ORD-010 | AT RISK | Cold Chain → Jewish General Oncology (C039) | Expected: 2026-05-30
Open Actions:
- ACT-007: Trastuzumab exception at Sunnybrook Oncology — ESCALATED TO CHIEF ⚡ (Raised: 2026-05-26)
Why This Matters:
Sunnybrook Oncology has BOTH a delayed order AND a short-shipped exception outstanding simultaneously.
Trastuzumab (P036) is a biologic oncology therapy — no substitution. This situation has already been flagged to the Chief.
Cold chain integrity during delays must be verified.
Recommended Actions:
- Confirm Chief escalation ACT-007 is actively being managed
- Demand proof of cold chain integrity for ORD-005 in transit
- Request immediate partial shipment from OncoBio to address Sunnybrook shortfall
- Monitor ORD-010 Jewish General Oncology closely — escalate if status worsens
🔴 RANK 3 — ImmunoRx Supply (S010)
Risk Level: CRITICAL
On-Time Delivery Rate: 87%
Open Exceptions: 2
Delivery Status: On Track (overall), but multiple exceptions active
Shipment Method: Cold Chain ⚠️
Active Risk to Critical Care Clients:
- ORD-004 | DELAYED | Urgent | Cold Chain → Jewish General Oncology (C039) | Expected: 2026-05-27 (OVERDUE)
- ORD-052 | Exception - Short Shipped | Urgent | Cold Chain → INVIVA Toronto (C029) | Expected: 2026-05-23 (OVERDUE)
Open Actions:
- ACT-005: Adalimumab (P040) delayed — Expedite request sent to ImmunoRx (In Progress)
Why This Matters:
Both overdue orders serve high-acuity clients — an oncology clinic and an INVIVA infusion centre.
Adalimumab (P040) is a biologic immunosuppressant used in infusion therapy. Cold chain delays compromise product viability.
INVIVA Toronto already has a short-shipped exception outstanding.
Recommended Actions:
- Follow up on ACT-005 expedite request — confirm new ETA for ORD-004
- Verify cold chain compliance for ORD-004 during delay
- Escalate ORD-052 short-shipped exception to Procurement for emergency resupply
- Assess whether INVIVA Toronto can source from DC-QC-E as interim support
🟠 RANK 4 — CardioSupply Co (S003)
Risk Level: AT RISK
On-Time Delivery Rate: 85%
Open Exceptions: 3
Delivery Status: AT RISK
Shipment Method: Ground
Active Risk to Critical Care Clients:
- ORD-002 | DELAYED | Urgent → Toronto General Hospital (C025) | Expected: 2026-05-26 (OVERDUE)
- ORD-050 | Exception - Damaged | Urgent → Thunder Bay IDA (not critical care, but flag)
Open Actions:
- ACT-001: Amlodipine 5mg (P007) critical — Reorder 600 units raised for Toronto General Hospital (Open)
Why This Matters:
Toronto General Hospital has a delayed order AND a critical stock reorder open simultaneously.
Amlodipine is a cardiovascular medication — high clinical dependency for hospital inpatients.
Recommended Actions:
- Approve ACT-001 reorder urgently and confirm delivery timeline
- Contact CardioSupply Co for updated ETA on ORD-002
- Assess cross-DC stock transfer from DC-QC-W to support DC-ON if delay extends past May 31
🟠 RANK 5 — EndoPharm (S008)
Risk Level: AT RISK
On-Time Delivery Rate: 68% ⚠️ BELOW 70% THRESHOLD
Open Exceptions: 6
Delivery Status: AT RISK
Shipment Method: Ground
Active Risk to Critical Care Clients:
- ORD-008 | AT RISK → MS Clinic Toronto (C028) | Expected: 2026-05-29
- ORD-038 | In Transit → MS Clinic Toronto (C028) | Expected: 2026-05-29
Open Actions:
- ACT-009: Supplier performance review scheduled — 3 exceptions this month (Scheduled)
Why This Matters:
EndoPharm's on-time rate has breached the 70% systemic risk threshold.
MS Clinic Toronto (Neurology) has two concurrent orders from this supplier — one AT RISK.
6 open exceptions make this a systemic reliability issue, not an isolated incident.
Recommended Actions:
- Ensure ACT-009 performance review proceeds immediately
- Formally place EndoPharm on the supplier watchlist
- Identify backup supplier coverage for EndoPharm product lines (P031–P035)
- Escalate to Chief if ORD-008 is not received by end of day May 29
🟠 RANK 6 — BioRx Logistics (S004)
Risk Level: AT RISK
On-Time Delivery Rate: 60% ⚠️ CRITICAL — LOWEST IN NETWORK
Open Exceptions: 8
Contract Type: Secondary
Delivery Status: AT RISK
Active Risk to Critical Care Clients:
- ORD-012 | AT RISK → BC Cancer Agency (C005) | Expected: 2026-06-02
Open Actions:
- ACT-003: BioRx on-time rate dropped to 60% — Escalated to watchlist (Open)
Why This Matters:
BioRx has the worst on-time delivery rate in the entire supplier network at 60%.
8 open exceptions is the highest exception count of any supplier.
Although only one critical care order is currently in the system for BioRx, its systemic unreliability poses a growing risk as a Secondary supplier used for backup coverage.
Recommended Actions:
- Confirm ACT-003 watchlist escalation has been formally reviewed by Supplier Relations
- Evaluate whether BioRx contract should be suspended or renegotiated
- Remove BioRx from backup supplier pool for any critical care client until OTR improves
- Flag BC Cancer Agency ORD-012 for close monitoring
⚡ RECOMMENDED PRIORITY ACTIONS — TODAY (May 29, 2026)
- IMMEDIATE — Activate NovaDist Backup (S014) for INVIVA Edmonton and INVIVA Toronto cold chain orders
- IMMEDIATE — Confirm Chief escalation ACT-007 (Trastuzumab / Sunnybrook Oncology) is being actioned
- URGENT — Follow up on ACT-005 expedite request to ImmunoRx for Jewish General Oncology
- URGENT — Approve emergency PO ACT-004 for QEII Health Sciences Halifax (Ciprofloxacin)
- TODAY — Initiate formal supplier review for EndoPharm — OTR below 70% threshold
- TODAY — Evaluate BioRx Logistics contract — 60% OTR and 8 open exceptions is unsustainable
📋 SUPPLIER RISK SUMMARY
- S002 | NovaDist Health | 72% OTR | 5 Exceptions | DELAYED | Cold Chain | 🔴 CRITICAL
- S009 | OncoBio Canada | 90% OTR | 1 Exception | Exception Orders Active | Cold Chain | 🔴 CRITICAL
- S010 | ImmunoRx Supply | 87% OTR | 2 Exceptions | Exception Orders Active | Cold Chain | 🔴 CRITICAL
- S003 | CardioSupply Co | 85% OTR | 3 Exceptions | AT RISK | Ground | 🟠 AT RISK
- S008 | EndoPharm | 68% OTR | 6 Exceptions | AT RISK | Ground | 🟠 AT RISK
- S004 | BioRx Logistics | 60% OTR | 8 Exceptions | AT RISK | Ground | 🟠 AT RISK
Report generated by Supply Chain Intelligence | Intelligence to Action
Desai Intelligence © 2026
🗺️ Provincial Supply Shortage Exposure Report
Supply Chain Intelligence
Report Date: May 29, 2026
Prepared for: Jaini Desai
Scope: All provinces | All distribution centres | Inventory + Orders + Clients + Actions
⚡ EXECUTIVE SUMMARY
Five provinces carry active supply shortage risk today. Ontario leads with the most severe and concentrated exposure, followed by Quebec and the Atlantic Region. Alberta and Manitoba carry secondary risk. British Columbia and Newfoundland have isolated exceptions under control.
📊 PROVINCIAL RISK OVERVIEW (Ranked by Severity)
- 🔴 Ontario (ON) | DC-ON | CRITICAL — Highest exposure in the network
- 🔴 Quebec (QC) | DC-QC-E / DC-QC-W | CRITICAL — Cold chain biologic risk at oncology clinics
- 🔴 Nova Scotia / Atlantic (NS, NB, PEI) | DC-ATL | CRITICAL — Antibiotic shortage at major hospital
- 🟠 Alberta (AB) | DC-AB | AT RISK — Cold chain insulin exception at INVIVA
- 🟠 Manitoba / Saskatchewan (MB/SK) | DC-MB | AT RISK — Hospital and respiratory supply disruption
- 🟠 British Columbia (BC) | DC-BC | AT RISK — Oncology order at risk + exception
- 🟠 Newfoundland (NL) | DC-NL | AT RISK — Controlled substance wrong product exception
🔴 RANK 1 — ONTARIO (ON)
Distribution Centre: DC-ON (Mississauga)
Risk Level: CRITICAL — Highest active exposure in the national network
Critical Clients Affected: Toronto General Hospital, Sunnybrook Oncology, INVIVA Toronto, MS Clinic Toronto, Brampton LTC
DELAYED Orders (All Urgent):
- ORD-001 | Insulin Glargine (P016) | Cold Chain ⚠️ | DELAYED → INVIVA Toronto (C029) | Expected: 2026-05-26 (OVERDUE)
- ORD-002 | Amlodipine 5mg (P007) | DELAYED → Toronto General Hospital (C025) | Expected: 2026-05-26 (OVERDUE)
- ORD-005 | Trastuzumab 440mg (P036) | Cold Chain ⚠️ | DELAYED → Sunnybrook Oncology (C027) | Expected: 2026-05-28
AT RISK Orders:
- ORD-006 | Atorvastatin 20mg (P006) | Urgent | AT RISK → Toronto IDA Pharmacy (C020) | Expected: 2026-05-29
- ORD-008 | Gabapentin 300mg (P031) | AT RISK → MS Clinic Toronto (C028) | Expected: 2026-05-29
- ORD-009 | Morphine Sulfate 10mg (P043) | Urgent | Controlled Substance ⚠️ | AT RISK → Brampton LTC (C030) | Expected: 2026-05-29
Active Exceptions:
- ORD-050 | Amlodipine 5mg (P007) | Exception - Damaged | Urgent → Thunder Bay IDA (C032)
- ORD-052 | Adalimumab 40mg (P040) | Exception - Short Shipped | Urgent | Cold Chain ⚠️ → INVIVA Toronto (C029)
- ORD-054 | Trastuzumab 440mg (P036) | Exception - Short Shipped | Urgent | Cold Chain ⚠️ → Sunnybrook Oncology (C027)
Critical Inventory (Feeding DC-ON):
- Trastuzumab 440mg (P036) | 18 units | 3 days of supply | CRITICAL | Cold Chain ⚠️
- Amlodipine 5mg (P007) | 70 units | 2 days of supply | CRITICAL
- Atorvastatin 20mg (P006) | 120 units | 3 days of supply | CRITICAL
- Adalimumab 40mg (P040) | 15 units | 2 days of supply | CRITICAL | Cold Chain ⚠️
- Morphine Sulfate 10mg (P043) | 80 units | 3 days of supply | CRITICAL | Controlled Substance ⚠️
Open Actions:
- ACT-001 | Reorder Raised | Amlodipine 600 units for Toronto General Hospital | Open
- ACT-007 | Escalated to Chief | Trastuzumab at Sunnybrook Oncology — patient impact risk | Escalated ⚡
- ACT-008 | Reorder Raised | Atorvastatin 1000 units | Open
Summary:
- 3 DELAYED orders (all Urgent)
- 3 AT RISK orders
- 3 active exceptions (Short Shipped x2, Damaged x1)
- 5 CRITICAL inventory products
- 1 Chief escalation
- 2 open reorders
- Cold chain and controlled substance flags active
🔴 RANK 2 — QUEBEC (QC)
Distribution Centres: DC-QC-E (Montreal) | DC-QC-W (Drummondville)
Risk Level: CRITICAL — Both disrupted orders are cold chain biologics for oncology
Critical Clients Affected: Jewish General Oncology (C039), INVIVA Montreal (C040), CHUM Montreal (C037)
DELAYED Orders:
- ORD-004 | Adalimumab 40mg (P040) | Cold Chain ⚠️ | Urgent | DELAYED → Jewish General Oncology (C039) | Expected: 2026-05-27 (OVERDUE)
AT RISK Orders:
- ORD-010 | Rituximab 500mg (P037) | Cold Chain ⚠️ | AT RISK → Jewish General Oncology (C039) | Expected: 2026-05-30
Critical Inventory (Feeding DC-QC-E / DC-QC-W):
- Adalimumab 40mg (P040) | 15 units | 2 days of supply | CRITICAL | Cold Chain ⚠️
- Rituximab 500mg (P037) | 28 units | 6 days of supply | AT RISK | Cold Chain ⚠️
Open Actions:
- ACT-005 | Expedite Requested | Adalimumab delayed — expedite sent to ImmunoRx | In Progress
Summary:
- 1 DELAYED order (Urgent, Cold Chain)
- 1 AT RISK order (Cold Chain)
- 2 cold chain biologic products at risk
- Jewish General Oncology is facing simultaneous delayed and AT RISK orders for two different oncology biologics
- Cold chain integrity during delay must be verified immediately
🔴 RANK 3 — NOVA SCOTIA / ATLANTIC REGION (NS, NB, PEI)
Distribution Centre: DC-ATL (Moncton, NB)
Risk Level: CRITICAL — Antibiotic at 1 day of supply for a major health system
Critical Clients Affected: QEII Health Sciences Halifax (C046), INVIVA Halifax (C049)
DELAYED Orders:
- ORD-003 | Ciprofloxacin 500mg (P002) | Urgent | DELAYED → QEII Health Sciences Halifax (C046) | Expected: 2026-05-28
Critical Inventory (Feeding DC-ATL):
- Ciprofloxacin 500mg (P002) | 40 units | 1 day of supply | CRITICAL
- Doxycycline 100mg (P003) | 35 units | 1 day of supply | CRITICAL
Open Actions:
- ACT-004 | Emergency PO Raised | Ciprofloxacin 800 units for ATL region | Pending Approval ⚡
Summary:
- 1 DELAYED urgent order to a major hospital
- 2 CRITICAL antibiotic products — both at 1 day of supply
- Emergency PO pending approval — must be actioned today
- INVIVA Halifax also served from DC-ATL — monitor closely
🟠 RANK 4 — ALBERTA (AB)
Distribution Centre: DC-AB (Calgary)
Risk Level: AT RISK — Cold chain insulin exception at INVIVA Edmonton
Critical Clients Affected: INVIVA Edmonton (C014), Foothills Medical Centre (C010)
Active Exceptions:
- ORD-049 | Insulin Glargine (P016) | Exception - Short Shipped | Urgent | Cold Chain ⚠️ → INVIVA Edmonton (C014) | Expected: 2026-05-22 (OVERDUE)
Critical Inventory (Feeding DC-AB):
- Insulin Glargine (P016) | 110 units | 4 days of supply | CRITICAL | Cold Chain ⚠️
Open Actions:
- ACT-002 | Exception Logged | Insulin Glargine short shipped by 40 units — INVIVA Edmonton notified | In Progress
- ACT-006 | Backup Supplier Flagged | NovaDist Backup (S014) identified for Insulin | Open
Summary:
- 1 active Short Shipped exception — cold chain biologic
- Insulin Glargine at 4 days of supply — CRITICAL
- Backup supplier identified but not yet activated
- Activation of NovaDist Backup (S014) should happen today
🟠 RANK 5 — MANITOBA / SASKATCHEWAN (MB/SK)
Distribution Centre: DC-MB (Winnipeg)
Risk Level: AT RISK — Hospital and respiratory supply under strain
Critical Clients Affected: Health Sciences Centre Winnipeg (C017)
AT RISK Orders:
- ORD-007 | Salbutamol Inhaler (P019) | AT RISK → Brandon Remedy'sRx (C019) | Expected: 2026-06-01
- ORD-011 | Metformin 850mg (P015) | AT RISK → Health Sciences Centre Winnipeg (C017) | Expected: 2026-05-28
AT RISK Inventory (Feeding DC-MB):
- Salbutamol Inhaler (P019) | 200 units | 5 days of supply | AT RISK
- Metformin 850mg (P015) | 270 units | 6 days of supply | AT RISK
Summary:
- 2 AT RISK orders — one serving a major hospital
- Both products approaching safety stock threshold
- No open actions yet — escalation recommended if ORD-011 not received by May 28
🟠 RANK 6 — BRITISH COLUMBIA (BC)
Distribution Centre: DC-BC (Surrey)
Risk Level: AT RISK — Oncology order at risk + antibiotic exception
Critical Clients Affected: BC Cancer Agency (C005), Vancouver General Hospital (C004)
AT RISK Orders:
- ORD-012 | Tiotropium Inhaler (P022) | AT RISK → BC Cancer Agency (C005) | Expected: 2026-06-02
Active Exceptions:
- ORD-053 | Ciprofloxacin 500mg (P002) | Exception - Damaged → Prince George Medicine Shoppe (C007)
Summary:
- 1 AT RISK order serving BC Cancer Agency (oncology)
- 1 Exception - Damaged (antibiotic, remote client)
- Ciprofloxacin is already CRITICAL nationally — this damaged exception compounds risk
- BioRx Logistics (S004) is the supplier behind ORD-012 — 60% OTR, already on watchlist
🟠 RANK 7 — NEWFOUNDLAND (NL)
Distribution Centre: DC-NL (St. John's)
Risk Level: AT RISK — Controlled substance wrong product exception
Critical Clients Affected: NL Long-Term Care (C053), Health Sciences NL (C052)
Active Exceptions:
- ORD-051 | Morphine Sulfate 10mg (P043) | Exception - Wrong Product | Urgent | Controlled Substance ⚠️ → NL Long-Term Care (C053) | Expected: 2026-05-25 (OVERDUE)
Open Actions:
- ACT-010 | Exception Logged | Wrong product shipped to NL LTC — return initiated | In Progress
Summary:
- 1 active Wrong Product exception — controlled substance — regulatory compliance risk
- Return initiated but replacement shipment status unknown
- Morphine Sulfate (P043) at 3 days of supply CRITICAL nationally — compounds local risk
- Isolated exposure, but controlled substance wrong-product exceptions require regulatory notification
⚡ RECOMMENDED PRIORITY ACTIONS — TODAY (May 29, 2026)
- ONTARIO — IMMEDIATE | Approve or confirm ACT-001 reorder (Amlodipine) for Toronto General Hospital — 2 days of supply remaining
- ONTARIO — IMMEDIATE | Confirm Chief escalation ACT-007 (Trastuzumab / Sunnybrook Oncology) is actively being resolved
- ATLANTIC — IMMEDIATE | Approve Emergency PO ACT-004 (Ciprofloxacin 800 units) for QEII Halifax — 1 day of supply left
- ALBERTA — URGENT | Activate NovaDist Backup (S014) for Insulin Glargine — INVIVA Edmonton short shipped and overdue
- QUEBEC — URGENT | Follow up on expedite ACT-005 for Adalimumab → Jewish General Oncology — cold chain delay now 2 days overdue
- MANITOBA — TODAY | Escalate if ORD-011 (Metformin → Health Sciences Winnipeg) not received by end of day
- NEWFOUNDLAND — TODAY | Confirm replacement shipment for ORD-051 wrong product exception — notify regulatory team for controlled substance compliance
📋 PROVINCIAL RISK SUMMARY
- 🔴 Ontario (ON) | DC-ON | 3 DELAYED + 3 AT RISK + 3 Exceptions | 5 CRITICAL products | Chief escalation active
- 🔴 Quebec (QC) | DC-QC-E / DC-QC-W | 1 DELAYED + 1 AT RISK | 2 Cold Chain biologic products | Oncology exposure
- 🔴 Nova Scotia / Atlantic | DC-ATL | 1 DELAYED | 2 CRITICAL antibiotics at 1 day supply | Emergency PO pending
- 🟠 Alberta (AB) | DC-AB | 1 Exception - Short Shipped | Insulin Glargine 4 days supply | INVIVA exposure
- 🟠 Manitoba / SK | DC-MB | 2 AT RISK orders | Hospital Metformin at risk | No actions raised yet
- 🟠 British Columbia (BC) | DC-BC | 1 AT RISK + 1 Exception | Oncology + antibiotic risk
- 🟠 Newfoundland (NL) | DC-NL | 1 Exception - Wrong Product | Controlled substance | Regulatory flag
Report generated by Supply Chain Intelligence | Intelligence to Action
Desai Intelligence © 2026
🔴 BioRx Logistics — Complete Failure Exposure Report
Prepared by: Supply Chain Intelligence
Date: May 29, 2026
Scenario: BioRx Logistics (S004) fails completely effective May 30, 2026
Prepared for: Supply Chain Leadership / Chief Supply Chain Officer
SUPPLIER PROFILE — BIORX LOGISTICS (S004)
- Supplier ID: S004
- Contract Type: Secondary (NOT the preferred supplier)
- On-Time Delivery Rate: 60% — BELOW the 70% systemic risk threshold
- Open Exceptions: 8 (highest in the network)
- Shipment Method: Ground
- Delivery Status: AT RISK
- Next Expected Delivery: June 3, 2026
- Action on File: ACT-003 — BioRx escalated to watchlist on May 23, 2026 due to on-time rate drop to 60%
- Backup Supplier: ⚠️ NONE IDENTIFIED in the system for products P019, P020, P021, P022
PRODUCTS SUPPLIED — INVENTORY STATUS
P019 — Salbutamol Inhaler (Respiratory / Generic)
- Current Stock: 200 units
- Safety Stock Threshold: 250 units
- Days of Supply Remaining: 5 days ← 🔴 AT RISK (already below safety stock)
- Reorder Status: AT RISK
- Cold Chain Required: No
- Controlled Substance: No
P020 — Montelukast 10mg (Respiratory / Generic)
- Current Stock: 858 units
- Safety Stock Threshold: 250 units
- Days of Supply Remaining: 38 days
- Reorder Status: OK
- Cold Chain Required: No
- Controlled Substance: No
P021 — Fluticasone Inhaler (Respiratory / Brand)
- Current Stock: 525 units
- Safety Stock Threshold: 250 units
- Days of Supply Remaining: 40 days
- Reorder Status: OK
- Cold Chain Required: No
- Controlled Substance: No
P022 — Tiotropium Inhaler (Respiratory / Brand)
- Current Stock: 584 units
- Safety Stock Threshold: 250 units
- Days of Supply Remaining: 12 days
- Reorder Status: OK
- Cold Chain Required: No
- Controlled Substance: No
ACTIVE ORDERS AT RISK — BioRx Logistics
ORD-007 | P019 — Salbutamol Inhaler
- Client: C019 — Brandon Remedy'sRx (Independent Pharmacy - Remedy'sRx)
- Province: Manitoba (MB)
- Serving DC: DC-MB
- Quantity Ordered: 500 units
- Expected Delivery: June 1, 2026
- Order Status: 🟠 AT RISK
- Priority Flag: Normal
- Shipment Method: Ground
- Inventory Impact: CRITICAL — P019 already AT RISK with only 5 days of supply. Loss of this 500-unit order would cause immediate stockout at DC-MB.
ORD-012 | P022 — Tiotropium Inhaler
- Client: C005 — BC Cancer Agency (Specialty Clinic - Oncology)
- Province: British Columbia (BC)
- Serving DC: DC-BC
- Quantity Ordered: 150 units
- Expected Delivery: June 2, 2026
- Order Status: 🟠 AT RISK
- Priority Flag: Normal
- Shipment Method: Ground
- Inventory Impact: MODERATE — P022 has 12 days of supply; losing this order accelerates risk. ⚠️ CLIENT IS AN ONCOLOGY CLINIC — requires immediate escalation.
ORD-026 | P020 — Montelukast 10mg
- Client: C002 — North Shore Guardian (Independent Pharmacy - Guardian)
- Province: British Columbia (BC)
- Serving DC: DC-BC
- Quantity Ordered: 300 units
- Expected Delivery: June 3, 2026
- Order Status: In Transit
- Priority Flag: Normal
- Shipment Method: Ground
- Inventory Impact: LOW — P020 has 38 days of supply. Manageable but order needs rerouting.
CLIENT EXPOSURE SUMMARY
# | Client | Type | Province | DC | Order | Product | Impact Level
1 | Brandon Remedy'sRx (C019) | Independent Pharmacy - Remedy'sRx | MB | DC-MB | ORD-007 | Salbutamol Inhaler | 🔴 CRITICAL
2 | BC Cancer Agency (C005) | Specialty Clinic - Oncology | BC | DC-BC | ORD-012 | Tiotropium Inhaler | 🔴 HIGH — Escalate
3 | North Shore Guardian (C002) | Independent Pharmacy - Guardian | BC | DC-BC | ORD-026 | Montelukast 10mg | 🟠 MODERATE
- Total Clients Directly Impacted: 3
- Total Orders at Risk: 3 (ORD-007, ORD-012, ORD-026)
- Total Units at Risk: 950 units (500 + 150 + 300)
- DCs Impacted: DC-MB, DC-BC
- Provinces Impacted: Manitoba (MB), British Columbia (BC)
PRODUCT RISK MATRIX POST-FAILURE
Product | Current Days of Supply | Status | Post-Failure Risk
P019 — Salbutamol Inhaler | 5 days | 🔴 AT RISK | IMMEDIATE STOCKOUT (DC-MB within days)
P022 — Tiotropium Inhaler | 12 days | 🟢 OK | ACCELERATED RISK (Oncology client affected)
P020 — Montelukast 10mg | 38 days | 🟢 OK | LOW — buffer exists
P021 — Fluticasone Inhaler | 40 days | 🟢 OK | LOW — no active open order
BACKUP SUPPLIER STATUS
⚠️ CRITICAL GAP: No backup supplier is currently identified in the system for any BioRx products (P019, P020, P021, P022).
- BioRx Logistics is listed as a Secondary supplier — it IS the backup for these products.
- There is no tertiary or alternate supplier on file.
- Immediate emergency sourcing or alternate manufacturer contact is required.
ESCALATION FLAGS
🔴 Immediate Escalation Required:
- BC Cancer Agency (C005) — Oncology clinic awaiting Tiotropium Inhaler (ORD-012). Any disruption to specialty clinic supply must be escalated to Chief Supply Chain Officer.
- Salbutamol Inhaler (P019) — Only 5 days of supply remaining. Complete BioRx failure means no replenishment. Stockout risk at DC-MB within days.
⚠️ Regulatory / Compliance Notes:
- No controlled substances are affected by BioRx failure.
- No cold chain products are affected by BioRx failure.
RECOMMENDED ACTIONS
Immediate (Today — May 29, 2026):
- ⚡ Emergency sourcing for P019 (Salbutamol Inhaler) — 5 days of supply only. Identify alternate manufacturers immediately. Contact DC-MB to assess buffer capacity.
- ⚡ Escalate ORD-012 (BC Cancer Agency) to Chief Supply Chain Officer — Oncology clinic at supply risk. Patient safety implication.
- ⚡ Place emergency hold / intercept on ORD-026 (ORD In Transit) — Contact BioRx to confirm current shipment status before full failure is confirmed.
Short-Term (Next 48–72 Hours):
- Identify and onboard a backup supplier for P019, P020, P021, P022 — No backup currently exists. This is a systemic gap.
- Contact alternate respiratory product manufacturers — Salbutamol and Tiotropium are the priority SKUs.
- Notify DC-MB and DC-BC — Prepare them for potential supply gaps. Assess if inter-DC transfer of Salbutamol stock from other DCs is feasible.
- Formally terminate or suspend BioRx Logistics contract — Already on watchlist (ACT-003). Complete failure is grounds for contract action.
Strategic:
- Reclassify respiratory products (P019–P022) as high-priority — These currently have no preferred supplier fallback. Procurement must establish a preferred contract.
- Conduct a full network backup supplier audit — Identify all other product lines with no backup supplier on file.
Report generated by Supply Chain Intelligence Agent | Intelligence to Action
Data as of May 29, 2026 12:30 UTC
🔴 Med America — Three-Scenario Supply Chain Risk Analysis
Prepared by: Supply Chain Intelligence Agent
Date: May 29, 2026
Prepared for: Supply Chain Leadership / Chief Supply Chain Officer
Classification: Internal — Supply Chain Command
SCENARIO RANKING SUMMARY — BY TOTAL CLIENT IMPACT
Rank | Scenario | Clients Impacted | Active Orders Lost | Units at Risk | DCs Affected | Provinces Affected | Severity
🥇 #1 | DC-ON Power Outage (48 hrs) | 14 clients | 16 orders | ~4,600 units | 1 DC (entire Ontario hub) | ON | 🔴 CATASTROPHIC
🥈 #2 | BioRx + CardioSupply Dual Failure | 11 clients | 11 orders | 5,080 units | 5 DCs | BC, AB, MB, ON, NL | 🔴 SEVERE
🥉 #3 | NovaDist Health Failure | 4 clients | 4 orders | 870 units | 2 DCs | ON, AB, MB | 🟠 HIGH
🥇 SCENARIO 1 (RANKED #1) — DC-ON Power Outage: 48 Hours
Most Clients Impacted | Highest Acuity Concentration | Cold Chain & Controlled Substance Destruction Risk
Overview
A 48-hour total power failure at DC-ON (Mississauga, Ontario) would freeze all inbound receiving, outbound dispatching, cold chain storage, and secure courier operations for the largest single distribution hub in the Med America network. This is a FACILITY-LEVEL event, not a supplier event — meaning ALL product lines and ALL client types are affected simultaneously.
DC-ON Client Register — 14 Clients Fully Offline
- C020 — Toronto IDA Pharmacy | Independent Pharmacy - IDA | ON | Urban
- C021 — Mississauga Guardian | Independent Pharmacy - Guardian | ON | Urban
- C022 — Ottawa Remedy'sRx | Independent Pharmacy - Remedy'sRx | ON | Urban
- C023 — Rexall Scarborough | Retail Chain - Rexall | ON | Urban
- C024 — Rexall Brampton | Retail Chain - Rexall | ON | Urban
- C025 — Toronto General Hospital | Hospital / Health System | ON | Urban ⚠️ ESCALATE
- C026 — Ottawa Civic Hospital | Hospital / Health System | ON | Urban ⚠️ ESCALATE
- C027 — Sunnybrook Oncology | Specialty Clinic - Oncology | ON | Urban 🔴 CHIEF ESCALATION
- C028 — MS Clinic Toronto | Specialty Clinic - Neurology | ON | Urban ⚠️ ESCALATE
- C029 — INVIVA Toronto | INVIVA Infusion Clinic | ON | Urban 🔴 CHIEF ESCALATION
- C030 — Brampton LTC Facility | Long-Term Care Facility | ON | Urban ⚠️ ESCALATE
- C031 — Sudbury Medicine Shoppe | Independent Pharmacy - Medicine Shoppe | ON | Regional
- C032 — Thunder Bay IDA | Independent Pharmacy - IDA | ON | Remote
- C033 — London Home Health Agency | Home Health Agency | ON | Regional
Total: 14 clients | 2 hospitals | 1 oncology clinic | 1 neurology clinic | 1 INVIVA infusion clinic | 1 LTC | 1 home health | 7 pharmacies/retail
Active Orders Frozen at DC-ON — 16 Orders
- ORD-001 | P016 — Insulin Glargine | C029 INVIVA Toronto | 200 units | DELAYED | Urgent | ❄️ COLD CHAIN
- ORD-002 | P007 — Amlodipine 5mg | C025 Toronto General Hospital | 400 units | DELAYED | Urgent
- ORD-005 | P036 — Trastuzumab 440mg | C027 Sunnybrook Oncology | 40 units | DELAYED | Urgent | ❄️ COLD CHAIN
- ORD-006 | P006 — Atorvastatin 20mg | C020 Toronto IDA Pharmacy | 800 units | AT RISK | Urgent
- ORD-008 | P031 — Gabapentin 300mg | C028 MS Clinic Toronto | 300 units | AT RISK | Normal
- ORD-009 | P043 — Morphine Sulfate 10mg | C030 Brampton LTC | 200 units | AT RISK | Urgent | 🔒 CONTROLLED SUBSTANCE
- ORD-017 | P013 — Clopidogrel 75mg | C025 Toronto General Hospital | 300 units | In Transit | Normal
- ORD-021 | P044 — Hydromorphone 2mg | C026 Ottawa Civic Hospital | 180 units | In Transit | Normal | 🔒 CONTROLLED SUBSTANCE
- ORD-023 | P009 — Metoprolol 50mg | C021 Mississauga Guardian | 600 units | In Transit | Normal
- ORD-024 | P024 — Escitalopram 10mg | C023 Rexall Scarborough | 450 units | In Transit | Normal
- ORD-030 | P033 — Levetiracetam 500mg | C031 Sudbury Medicine Shoppe | 350 units | In Transit | Normal
- ORD-035 | P045 — Oxycodone 5mg | C033 London Home Health | 160 units | In Transit | Normal | 🔒 CONTROLLED SUBSTANCE
- ORD-038 | P032 — Pregabalin 75mg | C028 MS Clinic Toronto | 280 units | In Transit | Normal
- ORD-050 | P007 — Amlodipine 5mg | C032 Thunder Bay IDA | 250 units | Exception-Damaged | Urgent
- ORD-052 | P040 — Adalimumab 40mg | C029 INVIVA Toronto | 60 units | Exception-Short Shipped | Urgent | ❄️ COLD CHAIN
- ORD-054 | P036 — Trastuzumab 440mg | C027 Sunnybrook Oncology | 30 units | Exception-Short Shipped | Urgent | ❄️ COLD CHAIN
Total: 16 active orders | ~4,600 units frozen | 3 cold chain orders | 3 controlled substance orders
Critical Risk Layers
❄️ COLD CHAIN DESTRUCTION RISK:
- Insulin Glargine (P016, ORD-001): 200 units, already CRITICAL at 4 days of supply nationally — any on-site cold storage would be compromised within hours of power loss
- Trastuzumab 440mg (P036, ORD-005 & ORD-054): Oncology biologic — total 70 units for Sunnybrook Oncology. Product already at 3 days supply nationally (CRITICAL)
- Adalimumab 40mg (P040, ORD-052): Immunology biologic — 60 units for INVIVA Toronto. Product already at 2 days supply nationally (CRITICAL)
- Any cold chain stock held in DC-ON warehouse would be at temperature excursion risk within 4–8 hours of power failure without generator backup
🔒 CONTROLLED SUBSTANCE RISK:
- Morphine Sulfate, Hydromorphone, and Oxycodone orders in the DC-ON pipeline
- Power failure may compromise secure courier chain-of-custody protocols
- Regulatory reporting obligation under CDSA if secure storage is breached
🏥 HIGH-ACUITY CLIENT CONCENTRATION:
- DC-ON serves Canada's largest concentration of high-acuity clients in the network
- Toronto General Hospital and Ottawa Civic Hospital both have active urgent orders in this DC
- Sunnybrook Oncology already has an active Chief escalation (ACT-007) on file — a DC outage would compound an existing crisis
Backup & Recovery Options
- Inter-DC diversion: DC-QC-W (Drummondville) or DC-QC-E (Montreal) are the geographically nearest DCs and could theoretically absorb some ON volume — but cold chain and secure courier capacity would need to be confirmed
- Remote clients (Thunder Bay, Sudbury): C031 and C032 are remote/regional — inter-DC diversion is logistically complex and may not be feasible in 48-hour window
- Generator protocol: If DC-ON has emergency generator capacity, cold chain storage preservation is achievable — this must be confirmed immediately
- Recovery timeline: 48-hour outage = minimum 24–36 additional hours of catch-up processing backlog post-restoration
Recommended Actions — DC-ON Outage
- 🔴 Immediately verify DC-ON emergency generator capacity — cold chain storage depends on it
- 🔴 Escalate Trastuzumab, Adalimumab, and Insulin Glargine cold chain status to Chief — patient safety risk
- ⚡ Activate DC-QC-W and DC-QC-E as emergency overflow DCs for urgent Ontario orders
- ⚡ Contact Toronto General Hospital, Sunnybrook Oncology, and INVIVA Toronto directly — notify of potential delay window
- ⚡ Engage controlled substance compliance team — document chain-of-custody for Morphine, Hydromorphone, Oxycodone
- 📋 Brief logistics team to prepare dispatch surge plan for post-outage restoration
🥈 SCENARIO 2 (RANKED #2) — BioRx Logistics + CardioSupply Co Simultaneous Failure
Widest Geographic Footprint | 5 of 8 DCs Impacted | 2 CRITICAL Cardiovascular Products
Overview
Simultaneous loss of BioRx Logistics (S004) and CardioSupply Co (S003) would be the broadest supplier-driven disruption in the network. CardioSupply Co is a Preferred supplier for 7 cardiovascular products, two of which are already CRITICAL. BioRx is a Secondary supplier for 4 respiratory products with one already AT RISK. Combined, this scenario impacts 11 unique client sites across 5 provinces with no backup supplier for any of the 11 affected products.
Supplier Profiles at Failure
CardioSupply Co (S003) — Preferred Supplier:
- Products: P006, P007, P008, P009, P010, P011, P012 (7 cardiovascular products)
- On-Time Rate: 85% | Open Exceptions: 3 | Status: AT RISK
- Backup Supplier: NONE
BioRx Logistics (S004) — Secondary Supplier:
- Products: P019, P020, P021, P022 (4 respiratory products)
- On-Time Rate: 60% | Open Exceptions: 8 | Status: AT RISK
- Already escalated to watchlist (ACT-003, May 23, 2026)
- Backup Supplier: NONE
Combined Product Inventory Status at Failure
CardioSupply Co Products:
- P006 — Atorvastatin 20mg: Stock 120 | Safety 400 | 3 days of supply — 🔴 CRITICAL
- P007 — Amlodipine 5mg: Stock 70 | Safety 400 | 2 days of supply — 🔴 CRITICAL
- P008 — Lisinopril 10mg: Stock 1,234 | Safety 400 | 18 days — 🟢 OK
- P009 — Metoprolol 50mg: Stock 1,172 | Safety 400 | 17 days — 🟢 OK
- P010 — Ramipril 5mg: Stock 1,084 | Safety 400 | 39 days — 🟢 OK
- P011 — Hydrochlorothiazide 25mg: Stock 512 | Safety 400 | 13 days — 🟢 OK
- P012 — Furosemide 40mg: Stock 575 | Safety 400 | 25 days — 🟢 OK
BioRx Logistics Products:
- P019 — Salbutamol Inhaler: Stock 200 | Safety 250 | 5 days of supply — 🟠 AT RISK
- P020 — Montelukast 10mg: Stock 858 | Safety 250 | 38 days — 🟢 OK
- P021 — Fluticasone Inhaler: Stock 525 | Safety 250 | 40 days — 🟢 OK
- P022 — Tiotropium Inhaler: Stock 584 | Safety 250 | 12 days — 🟢 OK
Immediate Stockout Timeline Without Replenishment:
- P007 (Amlodipine 5mg): STOCKOUT in 2 days — May 31, 2026
- P006 (Atorvastatin 20mg): STOCKOUT in 3 days — June 1, 2026
- P019 (Salbutamol Inhaler): STOCKOUT in 5 days — June 3, 2026
Active Orders Lost — 11 Orders Across 5 DCs
CardioSupply Co Orders (8 orders):
- ORD-002 | P007 — Amlodipine 5mg | C025 Toronto General Hospital | 400 units | DELAYED | Urgent | DC-ON 🔴
- ORD-006 | P006 — Atorvastatin 20mg | C020 Toronto IDA Pharmacy | 800 units | AT RISK | Urgent | DC-ON 🔴
- ORD-014 | P008 — Lisinopril 10mg | C010 Foothills Medical Centre | 700 units | In Transit | Normal | DC-AB
- ORD-023 | P009 — Metoprolol 50mg | C021 Mississauga Guardian | 600 units | In Transit | Normal | DC-ON
- ORD-031 | P010 — Ramipril 5mg | C015 Winnipeg IDA Pharmacy | 550 units | In Transit | Normal | DC-MB
- ORD-034 | P011 — Hydrochlorothiazide 25mg | C052 Health Sciences NL | 450 units | In Transit | Normal | DC-NL
- ORD-040 | P012 — Furosemide 40mg | C053 NL Long-Term Care | 380 units | In Transit | Normal | DC-NL
- ORD-050 | P007 — Amlodipine 5mg | C032 Thunder Bay IDA | 250 units | Exception-Damaged | Urgent | DC-ON
BioRx Logistics Orders (3 orders):
- ORD-007 | P019 — Salbutamol Inhaler | C019 Brandon Remedy'sRx | 500 units | AT RISK | Normal | DC-MB
- ORD-012 | P022 — Tiotropium Inhaler | C005 BC Cancer Agency | 150 units | AT RISK | Normal | DC-BC 🔴
- ORD-026 | P020 — Montelukast 10mg | C002 North Shore Guardian | 300 units | In Transit | Normal | DC-BC
Total: 11 orders | 5,080 units at risk | 5 DCs affected
Client Exposure — 11 Unique Clients
- C025 — Toronto General Hospital | Hospital / Health System | ON | DC-ON 🔴 ESCALATE
- C010 — Foothills Medical Centre | Hospital / Health System | AB | DC-AB 🔴 ESCALATE
- C052 — Health Sciences NL | Hospital / Health System | NL | DC-NL 🔴 ESCALATE
- C005 — BC Cancer Agency | Specialty Clinic - Oncology | BC | DC-BC 🔴 CHIEF ESCALATION
- C053 — NL Long-Term Care | Long-Term Care Facility | NL | DC-NL ⚠️ ESCALATE
- C020 — Toronto IDA Pharmacy | Independent Pharmacy - IDA | ON | DC-ON
- C021 — Mississauga Guardian | Independent Pharmacy - Guardian | ON | DC-ON
- C015 — Winnipeg IDA Pharmacy | Independent Pharmacy - IDA | MB | DC-MB
- C019 — Brandon Remedy'sRx | Independent Pharmacy - Remedy'sRx | MB | DC-MB
- C002 — North Shore Guardian | Independent Pharmacy - Guardian | BC | DC-BC
- C032 — Thunder Bay IDA | Independent Pharmacy - IDA | ON | DC-ON (Remote)
Total: 11 clients | 3 hospitals | 1 oncology clinic | 1 LTC | 6 pharmacies
Geographic spread: BC, AB, MB, ON, NL — 5 of 8 Canadian provinces in network
No Backup Suppliers Exist for Any Affected Product
- CardioSupply Co (Preferred) — no backup supplier on file for P006–P012
- BioRx Logistics (Secondary, was the backup) — no tertiary supplier on file for P019–P022
- ACT-008 (Atorvastatin reorder) and ACT-001 (Amlodipine reorder) are both open but depend on CardioSupply Co to fulfill
Recommended Actions — Dual Failure
- 🔴 Emergency source Amlodipine 5mg (P007) TODAY — 2-day stockout clock is running
- 🔴 Emergency source Atorvastatin 20mg (P006) TODAY — 3-day stockout clock is running
- 🔴 Escalate BC Cancer Agency (C005) and all 3 hospitals to Chief Supply Chain Officer
- ⚡ Contact alternate cardiovascular manufacturers immediately — no backup exists
- ⚡ Assess inter-DC Amlodipine and Atorvastatin stock transfer from DC-QC, DC-ATL to shore up DC-ON
- ⚡ Emergency source Salbutamol Inhaler (P019) — 5 days before stockout at DC-MB
- 📋 Open 11 new emergency POs — one per impacted order
- 📋 Notify Health Sciences NL and NL Long-Term Care — remotest impacted clients, longest lead times
🥉 SCENARIO 3 (RANKED #3) — NovaDist Health Complete Failure This Week
Fewest Clients | Highest Per-Client Severity | INVIVA + Hospital + Immunology | Cold Chain Products | Partial Backup Available
Overview
NovaDist Health (S002) is a Preferred Cold Chain supplier currently in DELAYED status with 5 open exceptions. A complete failure this week would cut supply to 4 high-acuity client sites across 3 DCs, affecting two CRITICAL diabetes medications — one of which (Insulin Glargine) is a cold chain product with only 4 days of national supply remaining. Although fewer clients are affected than other scenarios, the per-client severity is among the highest in the network.
Supplier Profile at Failure
NovaDist Health (S002) — Preferred Supplier:
- Products: P015, P016, P017, P018 (diabetes product portfolio)
- On-Time Rate: 72% (near systemic risk threshold of 70%)
- Open Exceptions: 5
- Shipment Method: Cold Chain
- Delivery Status: DELAYED
- Next Expected Delivery: May 28, 2026 (already past)
- Actions on File: ACT-002 (Insulin Glargine short shipped, In Progress) | ACT-006 (Backup flagged for P016/P017, Open)
Product Inventory Status at Failure
- P015 — Metformin 850mg: Stock 270 | Safety 300 | 6 days — 🟠 AT RISK | No cold chain | No backup supplier
- P016 — Insulin Glargine 100u/ml: Stock 110 | Safety 300 | 4 days — 🔴 CRITICAL | ❄️ Cold Chain | Partial backup: NovaDist Backup (S014) covers P016 ✓
- P017 — Insulin Aspart 100u/ml: Stock 976 | Safety 300 | 13 days — 🟢 OK | ❄️ Cold Chain | Partial backup: NovaDist Backup (S014) covers P017 ✓
- P018 — Sitagliptin 100mg: Stock 934 | Safety 300 | 24 days — 🟢 OK | No backup supplier
Critical Gap: NovaDist Backup (S014) only covers P016 and P017. P015 (Metformin, AT RISK) and P018 (Sitagliptin) have NO backup supplier.
Active Orders Lost — 4 Orders Across 2 DCs
- ORD-001 | P016 — Insulin Glargine | C029 INVIVA Toronto | 200 units | DELAYED | Urgent | ❄️ Cold Chain | DC-ON 🔴
- ORD-011 | P015 — Metformin 850mg | C017 Health Sciences Centre Winnipeg | 400 units | AT RISK | Normal | DC-MB ⚠️
- ORD-033 | P017 — Insulin Aspart | C011 Alberta Arthritis Clinic | 120 units | In Transit | Normal | ❄️ Cold Chain | DC-AB ⚠️
- ORD-049 | P016 — Insulin Glargine | C014 INVIVA Edmonton | 150 units | Exception - Short Shipped | Urgent | ❄️ Cold Chain | DC-AB 🔴
Total: 4 orders | 870 units at risk | DC-ON + DC-AB impacted
Client Exposure — 4 Clients
- C029 — INVIVA Toronto | INVIVA Infusion Clinic | ON | DC-ON 🔴 CHIEF ESCALATION
- C014 — INVIVA Edmonton | INVIVA Infusion Clinic | AB | DC-AB 🔴 CHIEF ESCALATION
- C017 — Health Sciences Centre Winnipeg | Hospital / Health System | MB | DC-MB ⚠️ ESCALATE
- C011 — Alberta Arthritis Clinic | Specialty Clinic - Immunology | AB | DC-AB ⚠️ ESCALATE
Total: 4 clients | 2 INVIVA infusion clinics | 1 hospital | 1 immunology specialty clinic
All 4 clients are high-acuity. Zero pharmacies or retail clients are impacted — this scenario is 100% concentrated in vulnerable clinical settings.
Backup Supplier Analysis
- NovaDist Backup (S014): On Track | 82% on-time | Cold Chain | Next delivery May 30, 2026
- Covers P016 (Insulin Glargine) ✓
- Covers P017 (Insulin Aspart) ✓
- Does NOT cover P015 (Metformin) ✗
- Does NOT cover P018 (Sitagliptin) ✗
- Partial mitigation is possible — but activation of S014 must happen immediately to offset the CRITICAL P016 gap
- P015 (Metformin, AT RISK, 6 days supply) has zero backup — emergency alternative sourcing required
Recommended Actions — NovaDist Failure
- 🔴 Activate NovaDist Backup (S014) immediately for P016 and P017 — do not wait for NovaDist confirmation of failure
- 🔴 Escalate INVIVA Toronto (C029) and INVIVA Edmonton (C014) to Chief Supply Chain Officer — Insulin Glargine supply for infusion patients is a patient safety event
- ⚡ Emergency source Metformin 850mg (P015) — 6 days of supply, no backup exists
- ⚡ Contact Health Sciences Centre Winnipeg (C017) directly — hospital dependent on Metformin order (ORD-011)
- ⚡ Expedite ORD-033 intercept — confirm if Insulin Aspart shipment (In Transit) can be rerouted to a functioning DC if NovaDist fails mid-delivery
- 📋 Formally terminate NovaDist preferred contract — 72% on-time rate, 5 open exceptions, and now complete failure grounds for termination
CROSS-SCENARIO COMPARISON — KEY METRICS
By Number of Clients Impacted:
- Scenario 1 (DC-ON Outage): 14 clients
- Scenario 2 (BioRx + CardioSupply): 11 clients
- Scenario 3 (NovaDist): 4 clients
By Number of Orders Lost:
- Scenario 1 (DC-ON Outage): 16 orders
- Scenario 2 (BioRx + CardioSupply): 11 orders
- Scenario 3 (NovaDist): 4 orders
By Units at Risk:
- Scenario 2 (BioRx + CardioSupply): 5,080 units
- Scenario 1 (DC-ON Outage): ~4,600 units
- Scenario 3 (NovaDist): 870 units
By Geographic Spread:
- Scenario 2 (BioRx + CardioSupply): 5 provinces, 5 DCs
- Scenario 3 (NovaDist): 3 provinces, 2 DCs
- Scenario 1 (DC-ON Outage): 1 province, 1 DC (but highest client concentration)
By Cold Chain Risk:
- Scenario 1 (DC-ON Outage): 🔴 HIGHEST — cold chain storage failure risk, product destruction possible
- Scenario 3 (NovaDist): Cold chain supply disruption only
- Scenario 2 (BioRx + CardioSupply): No cold chain products affected
By Controlled Substance Risk:
- Scenario 1 (DC-ON Outage): 🔴 Present — Morphine, Hydromorphone, Oxycodone
- Scenarios 2 & 3: No controlled substances affected
By Backup Availability:
- Scenario 3 (NovaDist): Partial backup available (S014 for P016, P017)
- Scenarios 1 & 2: No backup or alternate DCs immediately available
By Stockout Timeline:
- Scenario 2: P007 Amlodipine STOCKOUT in 2 days — fastest clock
- Scenario 1: P016 Insulin Glargine (on-site cold storage at risk within hours if no generator)
- Scenario 3: P016 at 4 days — manageable with immediate S014 activation
OVERALL RECOMMENDATION TO CHIEF SUPPLY CHAIN OFFICER
All three scenarios represent conditions that exist RIGHT NOW in the network. These are not hypothetical future risks — they are current vulnerabilities that could be triggered by a single adverse event.
Immediate Priority Actions (Today, May 29, 2026):
- Confirm DC-ON emergency generator and cold chain failover protocol — Scenario 1 can occur at any time
- Emergency source Amlodipine 5mg (P007) and Atorvastatin 20mg (P006) — Scenario 2 trigger products are already CRITICAL
- Activate NovaDist Backup (S014) preemptively for Insulin Glargine — do not wait for Scenario 3 to materialize
- Commission a formal backup supplier audit — zero backup suppliers exist for 9 of 11 products across Scenarios 2 and 3
- Convene a Supply Chain Risk Committee briefing — the simultaneous AT RISK status of BioRx, CardioSupply, and NovaDist represents a systemic fragility requiring strategic response
Report generated by Supply Chain Intelligence Agent | Intelligence to Action
Data as of May 29, 2026 12:30 UTC
Technical Decisions & What I Learned Building This
The agent instructions were written before any data files were attached — deliberately. The goal was to bake enough domain context into the instructions that the agent could reason about the problem even in isolation. Each specialist agent received rich, structured instructions covering its exact data domain, escalation rules, response formatting preferences, and current situation awareness. Character limits in Copilot Studio sit around 8,000 characters per agent — so every word had to earn its place.
The formatting instruction was a separate field entirely — I used the Response Formatting section to tell the agent: no tables, bullet points only, bold product names, use emoji status indicators (🔴 🟠 🟢). This was a deliberate decision after hitting a rendering problem early on.
Early responses were rendering as HTML tables — which looked fine in preview but broke completely in the Copilot Studio test panel. The columns were too narrow, text was wrapping awkwardly, and the citation markers were appearing as small numbered badges inside the table cells.
The fix was simple once I understood the root cause: the agent was defaulting to markdown table syntax because that's what LLMs do when presenting structured data. I added an explicit instruction in the Response Formatting field: "Never use markdown tables. Always use bullet point lists with clear labels." The responses became significantly more readable immediately.
Getting the conversation to flow correctly from greeting → adaptive card → specialist agent → back to greeting was the most time-consuming part of the build. The default Copilot Studio greeting topic ends with "End all topics" — which means after the agent responds, the conversation dies. The user has no way to ask a follow-up question without starting over.
The fix was to restructure the Greeting topic: delete the End all topics node, add the adaptive card directly in the greeting flow, build condition branches for each intent (briefing, inventory, supplier, orders, regional, actions), wire each condition to the appropriate specialist agent call, and then add a return path. The Start Over system topic also needed updating to redirect back to Greeting rather than just resetting.
This prototype uses small synthetic CSV files — 50 products, 14 suppliers, 54 orders, 53 clients. In a production environment at a pharmaceutical distributor, those files would be orders of magnitude larger — tens of thousands of SKUs, hundreds of suppliers, millions of order lines.
Copilot Studio's knowledge sources work well at this scale but would not handle raw enterprise data files directly. The production design would replace uploaded files with Power Automate flows that connect to approved organizational data sources — such as SharePoint, OneDrive, or existing internal systems via supported connectors — and return pre-filtered, summarized results to the agent. The agent reasons over a curated subset, not the full dataset. Azure AI Search would handle chunking and indexing for any document-heavy knowledge sources.
Child agents were the right choice for this prototype. They're fast to build, they inherit context from the parent orchestrator, and for a demo environment they demonstrate the multi-agent architecture clearly without the overhead of publishing and connecting standalone agents.
Phase 2 would move to external standalone agents for one specific reason: role-based access control. In a production deployment, an Inventory Analyst should only be able to access the Inventory Intelligence Agent — they should not see supplier performance data, order exceptions at other DCs, or executive action logs. An external agent can be deployed independently, connected to scoped data sources, and access-controlled via Azure AD groups. The orchestrator remains the management layer for users with broader permissions — Regional Managers and the Chief Supply Chain Officer.
The conversation routing pattern is identical between child and external agents. The difference is purely in the deployment and access model.
Adaptive Card → Intent Variable: When a user clicks a button on the adaptive card it sends a structured intent value — "inventory", "supplier", "orders", "regional", "briefing". Condition nodes read this variable directly and route to the right specialist agent. Most reliable routing for button-driven interactions — bypasses the trigger system entirely.
Topics → "The Agent Chooses": Each specialist topic has a rich description of what it handles. The generative orchestrator reads all descriptions and decides which topic to invoke based on natural language intent. A user typing "what cold chain products are we running low on" correctly routes to the Inventory Intelligence topic without that phrase being pre-programmed. Flexible, handles natural language well.
Specialist Agents → Invoked trigger: Child agents use the "It's invoked" trigger type — meaning they only activate when explicitly called by the orchestrator, never independently. This keeps routing controlled and prevents agents from firing on unintended inputs.
Design principle: use intent variables for structured UI interactions, generative triggers for natural language routing, invoked triggers for specialist agents.
Appendix — Copilot Studio Build Screenshots
The following screenshots are from the live Copilot Studio prototype running under the jd_intelligence environment.
Agents tab showing all 5 child agents built and enabled: Action Management, Inventory Intelligence, Order Tracking, Regional Intelligence, and Supplier Intelligence. Each is triggered by the generative orchestrator based on user intent.
Knowledge tab showing all 5 synthetic data files loaded and ready. Each file covers a separate domain: inventory, suppliers, orders, clients, and action log. Status shows Ready for all sources.
The Greeting topic canvas showing the complete conversation flow: trigger → welcome message → adaptive card with 5 buttons → 6 condition branches (briefing, inventory, supplier, orders, regional, actions) → specialist agent calls. Each condition routes to a different child agent with UserQuery as input.
The test panel showing a live cross-domain response to the query "If BioRx Logistics fails completely tomorrow what is our total client exposure?" — with source citations visible at bottom right referencing the specific knowledge files used.
The agent automatically opens with a structured Situation Overview block — 8 CRITICAL products, 5 DELAYED orders, 6 exceptions, 10 open actions — before proceeding into full section detail.
Section 8 — Regional Exposure Snapshot — was generated automatically by the agent synthesizing client, order, and inventory data by DC and province.
The briefing closes with 5 ranked priorities and cites all 5 knowledge sources used to generate the response.
